| REVIEW ARTICLE |
|
| Year : 2018 | Volume
: 38
| Issue : 4 | Page : 137-143 |
|
|
Diffuse large B-Cell lymphoma-review
Rajeshwar Singh1, AP Dubey1, Anvesh Rathore1, Rajan Kapoor1, Durgesh Sharma2, Nilabh Kumar Singh2, Sachin Maggo2
1 Department of Haematology and Medical Oncology, Army Hospital Research & Referral, New Delhi, India
2 Department of Medicine, Army Hospital Research & Referral, New Delhi, India
Correspondence Address:
Dr. A P Dubey
Department of Medical Oncology, Army Hospital (Research and Referral), New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jmedsci.jmedsci_147_17
|
|
|
Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 30 percent of all NHL cases, involving both nodal and extra-nodal sites. Apart from distinct morphological and clinicopathological subtypes, DLBCL can be dived into molecular subtypes, Germimal Centre Subtype (GCB) and Activated B-Cell (ABC) based on gene expression profiling. IPI (International Prognostication Index) and its variants are used to prognosticate the patients. Limited stage DLBCL is primarily treated with combined modality therapy consisting of abbreviated systemic chemotherapy (three cycles), and involved field radiation therapy, whereas advanced stage disease is treated with full course of chemotherapy with recommendation of addition of novel agents ( Bortezomib, Ibrutinib, Lenalidomide) in ABC type DLBCL. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
